SPVX02 Clears Phase I in 60 Adults as Fridge-Free Vaccine Stays Potent 2 Years at 30C
Updated
Updated · uhs.nhs.uk · Aug 5
SPVX02 Clears Phase I in 60 Adults as Fridge-Free Vaccine Stays Potent 2 Years at 30C
3 articles · Updated · uhs.nhs.uk · Aug 5
Summary
60 healthy adults in a randomized Phase I trial showed no vaccine-related serious adverse events, and all SPVX02 recipients reached protective tetanus and diphtheria antibody levels by day 28.
Published in eClinicalMedicine, the data showed immune responses comparable to licensed vaccines and support the reformulated shot’s use without refrigeration.
SPVX02 remained effective for at least two years at up to 30C and stayed fully potent after three temperature swings from -20C to +40C; researchers are testing whether stability can extend to four years.
Stablepharma has already launched a Phase 2b study in a larger group and expects to complete SPVX02’s clinical development by 2027.
The advance targets a major supply problem: the WHO says about half of vaccines are wasted globally each year, often because cold-chain failures spoil doses before they reach remote or conflict-affected areas.
Could the 'resurrection plant' sugar that keeps this vaccine stable without refrigeration eventually eliminate all medical cold chains globally?
If rapid new sensors can instantly detect vaccine spoilage, will traditional refrigerated vaccines become obsolete before this powder hits the market?
While this fridge-free powder survives extreme heat, could mixing it with local water in remote areas introduce deadly new contamination risks?
From Lab to Last Mile: StablevaX™ Thermostable Vaccines Achieve Phase 1 Success and Chart a Path to Fridge-Free Immunization
Overview
The StablevaX™ platform uses trehalose to form a sugar glass that traps and protects vaccine molecules, allowing them to stay potent for years at high temperatures. This technology, delivered through a syringe-sponge system, simplifies vaccine storage and transport by reducing reliance on refrigeration. However, proper reconstitution—like vigorous flicking of the syringe—is essential to ensure full vaccine effectiveness. By making vaccines thermostable, StablevaX™ can cut costs, lower carbon emissions, and improve access in remote areas. Recent clinical trials show that SPVX02, a fridge-free tetanus-diphtheria vaccine, is safe, effective, and stable, marking a major step toward overcoming global cold chain barriers.